Not exact matches
Actual results and the timing of events could differ materially from those anticipated in the forward - looking statements due to these risks and uncertainties as well as other factors, which include, without limitation: the uncertain timing of, and risks relating to, the executive search process; risks related to the potential failure of eptinezumab to demonstrate safety and
efficacy in clinical
testing; Alder's ability to
conduct clinical trials and studies of eptinezumab sufficient to achieve a positive completion; the availability of data at the expected times; the clinical, therapeutic and commercial value of eptinezumab; risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability to obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights of others; the uncertain timing and level of expenses associated with Alder's development and commercialization activities; the sufficiency of Alder's capital and other resources; market competition; changes in economic and business conditions; and other factors discussed under the caption «Risk Factors» in Alder's Annual Report on Form 10 - K for the fiscal year ended December 31, 2017, which was filed with the Securities and Exchange Commission (SEC) on February 26, 2018, and is available on the SEC's website at www.sec.gov.
The company plans in October to
conduct a separate
test specifically to study the seasonal flu vaccine's effectiveness among 480 elderly participants (a demographic often encouraged to get seasonal flu shots), and Phase III
efficacy trials across a larger set of demographics are scheduled to begin early next year.
The researcher and his team confirmed this through extensive
efficacy and safety
testing, which was
conducted in cooperation with a research institute.
To
test the
efficacy of an intervention including buprenorphine, a medication that reduces opioid cravings and helps to prevent relapse to opioid use, the Yale team — lead by D'Onofrio and Dr. David Fiellin, professor of medicine —
conducted a randomized trial of more than 300 opioid - dependent individuals in an urban teaching hospital.
In collaboration with researchers at the University of California, San Francisco Memory and Aging Center, they are now
conducting a clinical trial to
test the drug's
efficacy in Alzheimer's patients.
Based on proof - of - concept pre-clinical studies indicating robust
efficacy and favorable safety profile, the company is now advancing to
conduct a clinical trial
testing the
efficacy of this new treatment.
The HVTN is an international collaboration that
conducts all phases of clinical trials, from evaluating experimental vaccines for safety and the ability to stimulate immune responses, to
testing vaccine
efficacy.
In this presentation, we discuss data from studies
conducted with academic, clinical, and industry collaborators that demonstrates the utility of the system as a more predictive, human - relevant alternative for
efficacy and safety
testing of new chemical entitites.
Its Clinical Trials Center
conducts 13 - 15 clinical studies per year, and in December initiated a Phase 2 clinical trial of an Ebola vaccine following its groundbreaking first - in - human
testing of the Ebola vaccine that showed
efficacy in Guinea last year.
Glenda Gray, executive director of the Wits Health Consortium's perinatal HIV research unit in South Africa, presented data today at the HIV R4P conference in Cape Town indicating that the prime - boost vaccine candidates initially
tested in the RV144 trial in Thailand — the only HIV vaccine trial to date to show any
efficacy — induced cross-clade immune responses in a Phase I safety trial
conducted in South Africa, with immunogenicity similar to or greater than that of the responses induced in Thai volunteers.
Most therapeutic research involving the
testing of new drugs is
conducted in highly regulated phases that study dosage, safety,
efficacy and long - term side effects:
A team of researchers from the University of Wisconsin — Madison School of Medicine and Public Health
conducted a randomized controlled trial in 2010 to
test the
efficacy of this common cold treatment.
Dr. Bry's systematic program of prevention research has included studies that: 1) search for precursors that differentiate adolescents who will develop
conduct or substance use problems from those who will not and environmental factors that might reduce or buffer those precursors; 2) investigate whether these factors actually precede or reduce future problems; and 3)
test the outcome
efficacy and effectiveness of experimental methods to modify these factors.
The patents considered in «elevated Promise» cases arguably have fairly clear technical deficiencies — for example, claiming a group of compounds where admittedly many of the compounds did not even have minimal activity [1]; asserting a new compound is an effective, less irritating eye drug, when admittedly eye drugs must have chronic safety
tests and no
tests had been done [2]; asserting a compound has clinical safety /
efficacy, when in fact only preliminary
tests had been
conducted [3].
Scientist / Lab Supervisor • Oversaw team activities including quality control, batch release, and legal compliance • Responsible for team training, work assignments, and overall product development • Developed training materials which cut training time by 50 % while increasing
efficacy • Directed investigations regarding corrective actions and preventative actions • Restructured
testing process reducing
testing time and expense by 50 % •
Conducted internal audits to ensure professional and efficient operations • Authored IQ, OQ, and PQ plans, protocols, methods, and summary reports • Reduced batch cycle time from 6 months to 4 weeks by creating of cross functional team • Motivated team members resulting in company loyalty and increased productivity
A pilot
test was
conducted to provide preliminary data on the
efficacy of the StandUp program in a U.S. high school.